Tevogen Bio Holdings (TVGN) AI Stock Analysis

• Market Cap: $237.22M
• Dividend Yield: N/A
• Average Volume (3M): 1.28M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.02
• Revenue Growth: N/A
• EPS Growth: -20.39%
• Country: US
• Employees: 18
• Sector: Financial
• Sector Strength: 82
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 183,893,430
• 10 Day Avg. Volume: 468,408
• 30 Day Avg. Volume: 1,275,045
• PEG Ratio: -0.02
• Price to Book (P/B): -29.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -16.71
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: 509.47
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -42.33
• 1Y Price Target: $10.00
• Price Target Upside: 663.36% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 33 Underperform
• Price Target: ―

Tevogen Bio Holdings faces substantial financial risks due to consistent losses and high leverage, which are typical in its industry. Technical analysis indicates a bearish trend, and valuation metrics show speculative investment characteristics. However, the recent corporate event involving a strategic agreement provides a positive outlook for operational advancements, slightly balancing the financial and technical concerns.

Tevogen Bio Holdings Business Overview & Revenue Model

Company Description

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

How the Company Makes Money

Tevogen Bio Holdings generates revenue primarily through the development and commercialization of its proprietary immunotherapy products. The company's revenue model includes income from product sales, licensing agreements, and strategic partnerships with pharmaceutical companies and research institutions. Additionally, Tevogen Bio may receive funding through grants and collaborations aimed at advancing its research initiatives. As the company progresses through clinical trials and secures regulatory approvals, sales of approved therapies are expected to be a significant revenue stream. Strategic alliances and partnerships also play a crucial role in expanding market reach and driving earnings.

Tevogen Bio Holdings Financial Statement Overview

Summary

Tevogen Bio Holdings is facing significant financial challenges with consistent operational losses, high leverage due to negative equity, and negative cash flow from operations. These factors suggest substantial financial risks, which are common in the biotech industry during early development stages.

Income Statement

Tevogen Bio Holdings has shown consistent negative EBIT and net income over the years with no revenue reported. The lack of revenue growth and recurring losses highlight challenges in achieving profitability. This is typical for biotechnology firms in the development phase but poses a risk to financial stability.

Balance Sheet

The company exhibits a high debt-to-equity ratio due to negative equity, reflecting high leverage and potential financial instability. Total assets have decreased significantly, and equity is negative, indicating financial distress. The negative equity also reflects accumulated losses over time.

Cash Flow

Tevogen's cash flow statement reveals negative operating and free cash flows, indicating cash burn typical of early-stage biotech companies. However, financing activities provided positive cash flow, suggesting reliance on external funding for operations. The absence of positive cash flow from operations poses sustainability risks.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00
	EBIT
-53.56M	―	-13.72M	-4.62M
	EBITDA
-53.56M	188.71K	-953.08K	-28.75K
	Net Income Common Stockholders
-13.73M	-67.33K	4.41M	-15.60M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.28M	8.84K	129.19K	7.12M
	Total Assets
3.46M	17.04M	357.14M	7.66M
	Total Debt
2.89M	1.63M	40.01M	23.48M
	Net Debt
1.60M	1.62M	39.88M	16.36M
	Total Liabilities
10.14M	17.73M	15.06M	24.15M
	Stockholders Equity
-6.67M	-695.80K	342.08M	-16.49M
Cash Flow		Free Cash Flow
-12.00M	-1.38M	-694.44K	-5.38M
	Operating Cash Flow
-12.00M	-1.38M	-215.40K	-5.27M
	Investing Cash Flow
0.00	342.92M	―	-109.73K
	Financing Cash Flow
12.23M	-341.66M	7.50K	12.50M

Tevogen Bio Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.31
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVGN, the sentiment is Positive. The current price of 1.31 is above the 20-day moving average (MA) of 1.14, above the 50-day MA of 1.10, and above the 200-day MA of 1.12, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 66.76 is Neutral, neither overbought nor oversold. The STOCH value of 69.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TVGN.

Tevogen Bio Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	64 Neutral	$12.77B	9.79	7.55%	17015.06%	12.20%	-6.98%
CDTX	48 Neutral	$311.28M	―	-299.58%	―	-99.35%	-260.33%
NVCT	48 Neutral	$201.83M	―	-115.28%	―	―	22.99%
CDXS	46 Neutral	$211.25M	―	-115.53%	―	-32.89%	-5.03%
CRVS	41 Neutral	$283.01M	―	-100.13%	―	―	-71.53%
CRGX	40 Underperform	$191.37M	―	-65.94%	―	―	―
TVGN	33 Underperform	$237.22M	―	-124.74%	―	―	-20.39%

Tevogen Bio Holdings Corporate Events

Tevogen Bio Signs Agreement with CD 8 Technology

On April 17, 2025, Tevogen Bio Holdings Inc. announced a Master Services and Facilities Agreement with CD 8 Technology Services LLC to access specialized manufacturing facilities for cell therapy production. This agreement is a strategic move to enhance Tevogen’s in-house production capabilities, aligning with its long-term strategy to accelerate development timelines, maintain operational agility, and control costs, thereby overcoming significant capital barriers typically faced in building GMP capabilities.

Spark’s Take on TVGN Stock

According to Spark, TipRanks’ AI Analyst, TVGN is a Underperform.

Tevogen Bio Holdings faces significant financial challenges, with operational losses and high leverage being key risks. Technical analysis indicates a bearish trend, and valuation metrics reflect the speculative nature typical of biotech firms in early development stages. However, recent funding announcements provide a positive outlook for strategic advancements, offering some mitigation to the financial risks.

To see Spark’s full report on TVGN stock, click here.